GPE
FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search
Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership
Orexo’s Opioid Overdose Nasal Spray Fails FDA Review for Second Time
Orexo, OX124, FDA, Nasal Spray, Opioid Overdose, Naloxone, Human Factors Study, Technical Data
GSK Headquarters Returns to Central London
GSK, Global Headquarters, Central London, The Earnshaw, Sustainability, Hybrid Working
Novartis to Wind Down San Diego Technical Research and Development Site by Mid-2025
Novartis, San Diego, Technical Research and Development, Site Closure, Layoffs, Restructuring
Grifols Founding Family and Brookfield Plan to Take Drugmaker Private
Grifols, Brookfield, Private Equity, Takeover Bid, Spanish Drugmaker, Nasdaq, Spanish Stock Exchange
Novo Nordisk Invests $4.1 Billion in New US Manufacturing Site, Abandoning Irish Plans
Novo Nordisk, US manufacturing site, obesity drugs, fill-finish facility, Clayton, NC, Irish build
Emergent Biosolutions Sells Baltimore Facility for $30 Million
Emergent Biosolutions, Baltimore facility, sale, Bora, $30 million
Syncona Expands Portfolio with Investments in iOnctura and Yellowstone, Two Cancer-Focused Biotechs
Syncona, iOnctura, Yellowstone, cancer biotechs, portfolio expansion, investment, biotechnology
Amber Therapeutics Raises $100M for Closed-Loop Neuromodulation Implant for Urinary Incontinence
Amber Therapeutics, urinary incontinence, neuromodulation, closed-loop implant, funding, series A round, pelvic pudendal nerve, mixed incontinence, U.S. regulatory approval.
Boehringer Ingelheim and Zealand Unveil Promising Fibrosis Data from Mid-Stage MASH Trial
Boehringer Ingelheim, Zealand, fibrosis, MASH trial, mid-stage, Phase II data, liver scarring, treatment